1887

Chapter 25 : Treatment of Parasitic Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Treatment of Parasitic Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816018/9781555813802_Chap25-1.gif /docserver/preview/fulltext/10.1128/9781555816018/9781555813802_Chap25-2.gif

Abstract:

Chemotherapy plays a very important role not only in reducing patient morbidity and mortality but also in reducing transmission of the parasitic infection. Many of the drugs used to treat parasitic infections have serious side effects; therefore, before initiation of therapy, it is important to consider the following factors: health of the patient, parasite drug resistance, accuracy of the original dose, potential drug toxicity, and the need for follow-up examinations to monitor therapy. This chapter talks about antiparasitic drugs that include albendazole, amphotericin B, amphotericin B, artemether and benznidazole. The systemic anthelmintic activity has been attributed to the primary metabolite, albendazole sulfoxide. Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of anticysticercal therapy. AmBisome treatment resulted in a lower incidence of chills, hypertension, hypotension, tachycardia, hypoxia, hypokalemia, and various events related to decreased kidney function compared with amphotericin B deoxycholate. Corticosteroids and adrenocorticotropic hormone may lead to hypokalemia. The drug may increase the bone marrow toxicity of ganciclovir. Probenecid may increase the levels of amphotericin B. The artemisinin-based combinations artemether- lumefantrine and artesunatemefloquine remain highly effective and elicit equivalent therapeutic responses in the treatment of highly drugresistant falciparum malaria. Benznidazole inhibits protein and RNA synthesis in ; it causes increased phagocytosis, cytokine release, and production of reactive mitogen intermediates that lead to death of the parasites.

Citation: Garcia L. 2007. Treatment of Parasitic Infections, p 718-757. In Diagnostic Medical Parasitology, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816018.ch25

Key Concept Ranking

Central Nervous System Diseases
1.2343407
Parasitic Diseases
1.1244137
Immune Systems
0.68559074
Ocular Infections
0.637261
Antimalarial Drugs
0.6125306
Lower Gastrointestinal Tract
0.55589336
Parasites
0.53258437
1.2343407
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555816018.ch25
1. Abramowicz, M. (ed.). 2004. Drugs for parasitic infections. Med. Lett. Drugs Ther. 46:112.
2. Alifrangis, M.,, S. Enosse,, R. Pearce,, C. Drakeley,, C. Roper,, I. F. Khalil,, W. M. Nkya,, A. M. Rønn,, T. G. Theander, and, I. C. Bygbjerg. 2005. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology. Am. J. Trop. Med. Hyg. 72:155162.
3. Alonso, D.,, J. Muñoz,, J. Gascón,, M. E. Valls, and, M. Corachan. 2006. Short Report: failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am. J. Trop. Med. Hyg. 74:342344.
4. Anonymous. 2006. Physicians’ Desk Reference, 60th ed. Medical Economics, Montvale, N.J.
5. Calvopina, M.,, R. H. Guderian,, W. Paredes,, M. Chico, and, P. J. Cooper. 1998. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans. R. Soc. Trop. Med. Hyg. 92:566569.
6. Crowell, A. L.,, C. E. Stephens,, A. Kumar,, D. W. Boykin, and, W. E. Secor. 2004. Evaluation of dicationic compounds for activity against Trichomonas vaginalis. Antimicrob. Agents Chemother. 48:36023605.
7. Dauchy, F. A.,, P. Vincendeau, and, F. Lifermann. 2006. Eight cases of fascioliasis: clinical and microbiological features. Med. Mal. Infect. 36:4246.
8. Del Brutto, O. H. 2005. Neurocysticercosis. Semin. Neurol. 25:243251.
9. el-Karaksy, H.,, B. Hassanein,, S. Okasha,, B. Behairy, and, I. Gadallah. 1999. Human fascioliasis in Egyptian children: successful treatment with triclabendazole. J. Trop. Pediatr. 45:135138.
10. Gilbert D. N.,, R. C. Moellering, and, M. A. Sande. 2003. The Sanford Guide to Antimicrobial Therapy, 33rd ed. Antimicrobial Therapy Inc., Dallas, Tex.
11. Kuhn, S.,, M. J. Gill, and, K. C. Kain. 2005. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune North American traveler to West Africa. Am. J. Trop. Med. Hyg. 72:407409.
12. Leang, B.,, L. Lynen,, W. Schrooten, and, J. Hines. 2005. Comparison of albendazole regimen for prophylaxis of Strongyloides hyperinfection in nephrotic syndrome patients on long-term steroids in Cambodia. Trop. Doct. 35:212213.
13. Moon, T. D.,, and R. A. Oberhelman. 2005. Antiparasitic therapy in children. Pediatr. Clin. North Am. 52:917948.
14. Moore, D. A.,, R. W. Girdwood, and, P. L. Chiodini. 2002. Treatment of anisakiasis with albendazole. Lancet 360:54.
15. Murray, H. W.,, J. D. Berman,, C. R. Davies, and, N. G. Saravia. 2005. Advances in leishmaniasis. Lancet. 366:15611577.
16. Nduati, E. W.,, and E. M. Kamau. 2006. Multiple synergistic interactions between atovaquone and antifolates against Plasmodium falciparum in vitro: a rational basis for combination therapy. Acta Trop. 31 Jan. [Epub ahead of print.]
17. Nguyen-Dinh, P.,, and W. E. Secor. 2003. Susceptibility test methods: parasites, p. 2108–2113. In P. R. Murray,, E. J. Baron,, J. H. Jorgenson,, M. A. Pfaller, and, R. H. Yolken (ed.), Manual of Clinical Microbiology, 8th ed., ASM Press, Washington, D.C.
18. Noedl, H.,, C. Wongsrichanalai, and, W. H. Wersndorfer. 2003. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. 19:176181.
19. Shanks, G. D.,, and M. D. Edstein. 2005. Modern malaria chemoprophylaxis. Drugs 65:20912110.
20. Secor, W. E.,, and P. Nguyen-Dinh. 2003. Mechanisms of resistance to antiparasitic agents, p. 2098–2107. In P. R. Murray,, E. J. Baron,, J. H. Jorgenson,, M. A. Pfaller, and, R. H. Yolken (ed.), Manual of Clinical Microbiology, 8th ed. ASM Press, Washington, D.C.
21. Singh, N.,, and A. Dube. 2004. Fluorescent Leishmania: application to anti-leishmanial drug testing. Am. J. Trop. Med. Hyg. 71:400402.
22. Siripanth, C.,, B. Punpoowong,, P. Amarapal,, N. Thima,, B. Eampokalap, and, J. Kaewkungwal. 2004. Comparison of Cryptosporidium parvum development in various cell lines for screening in vitro drug testing. Southeast Asian J. Trop. Med. Public Health 35:540546.
23. Sweetman, S. (ed.). 2005. Martindale the Complete Drug Reference. The Pharmaceutical Press, London, United Kingdom.
24. Tripathi, R. P.,, R. C. Mishra,, N. Dwivedi,, N. Tewari, and, S. S. Verma. 2005. Current status of malaria control. Curr. Med. Chem. 12:26432659.
25. Vessière, A.,, A. Berry,, R. Fabre,, F. Benoit-Vical, and, J. F. Magnaval. 2004. Detection by real-time PCR of the Pfcrt T76 mutation, a molecular marker of chloroquine-resistant Plasmodium falciparum strains. Parasitol. Res. 93:57.
26. Zardi, E. M.,, A. Picardi, and, A. Afeltra. 2005. Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy 51:193196.

Tables

Generic image for table
Table 25.1

Drugs and dosages for treating parasitic infections

Citation: Garcia L. 2007. Treatment of Parasitic Infections, p 718-757. In Diagnostic Medical Parasitology, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816018.ch25
Generic image for table
Table 25.2

Antiparasitic drugs

Citation: Garcia L. 2007. Treatment of Parasitic Infections, p 718-757. In Diagnostic Medical Parasitology, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816018.ch25
Generic image for table
Table 25.3

Information on drug resistance and susceptibility testing for selected parasites

Citation: Garcia L. 2007. Treatment of Parasitic Infections, p 718-757. In Diagnostic Medical Parasitology, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816018.ch25

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error